R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
HSD17B13 (F8I1E) Rabbit mAb #23282
Filter:
- WB
- IP
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 30 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Immunohistochemistry (Paraffin) | 1:50 - 1:200 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
HSD17B13 (F8I1E) Rabbit mAb recognizes endogenous levels of total HSD17B13 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant protein fragment specific to human HSD17B13 protein. The antigen has been further characterized as corresponding to residues surrounding Ala89 of human HSD17B13 protein.
Background
HSD17B13, also known as hydroxysteroid 17-beta dehydrogenase 13, is a liver-enriched, hepatocyte-specific, lipid droplet-associated protein involved in the metabolism of steroid hormones (1). HSD17B13 has been linked to the development of non-alcoholic fatty liver disease (NAFLD), a condition characterized by the accumulation of fat in the liver that can lead to liver damage and inflammation (2). Hepatic expression of HSD17B13 is significantly upregulated in NAFLD patients relative to healthy individuals, with expression levels correlating with disease severity (3,4). Moreover, several loss-of-function variants in HSD17B13 are associated with a reduced risk of chronic liver disease and decreased disease severity of NAFLD (5,6). These findings suggest that HSD17B13 may be a potential therapeutic target for the treatment of liver fibrosis and NAFLD.
- Poutanen, M. and Penning, T.M. (2019) Mol Cell Endocrinol 489, 1-2.
- Zhang, H.B. et al. (2021) Front Mol Biosci 8, 824776.
- Su, W. et al. (2014) Proc Natl Acad Sci USA 111, 11437-42.
- Ma, Y. et al. (2019) Hepatology 69, 1504-1519.
- Abul-Husn, N.S. et al. (2018) N Engl J Med 378, 1096-1106.
- Kozlitina, J. et al. (2018) N Engl J Med 379, 1876-1877.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.